Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.57 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.53 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.53 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.53 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.53 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.53 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.53 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.53 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.53 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.53 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.53 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.53 |
| ▸ | GRIK4 | Q16099 | 1/20 | 0.53 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.53 |
| ▸ | PRKAG1 | P54619 | 6/20 | 0.50 |
| ▸ | PRKAA2 | P54646 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4309662 | 0.84 | EGLN1 (0.63) | EGLN1GRIN2DGRIN3BGRIA1GRIA2 | |
| SCHEMBL1258540 | 0.82 | EGLN1 (0.57) | EGLN1GRIN2DGRIN3BGRIA1GRIA2 | |
| SCHEMBL29414225 | 0.79 | KMT2A (0.46) | CHEK2RHEB | |
| SCHEMBL7152026 | 0.79 | HTR3E (0.57) | CHEK2F10 | |
| SCHEMBL3064168 | 0.79 | KMT2A (0.46) | CHEK2RHEB | |
| SCHEMBL416845 | 0.79 | FABP6 (0.55) | EGLN1LMNACHEK2F10 | |
| SCHEMBL1259264 | 0.78 | EGLN1 (0.54) | EGLN1GRIN2DGRIN3BGRIA1GRIA2 | |
| SCHEMBL9703926 | 0.78 | GRIN2D (0.74) | EGLN1GRIN2DGRIN3BGRIA1GRIA2 | |
| SCHEMBL9589724 | 0.78 | EGLN1 (0.41) | EGLN1GRIN2DGRIN3BGRIA1GRIA2 | |
| SCHEMBL4239948 | 0.74 | MAPKAPK2 (0.47) | LMNAGAAHTTCHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2742029-B1 | N-(BENZIMIMDAZOL-2-YL)-CYCLOPROPANE CARBOXAMIDES AS LYSOPHOSPHATIDIC ACID ANTAGONISTS | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-8912202-B2 | N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists | MERCK PATENT GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20140228378-A1 | N-(Benzimimdazol-2-yl)-Cyclopropane Carboxamides as Lysophosphatidic Acid Antagonists | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100048574-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20100004258-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-01-07 | — | — | US | disclosed |
| US-7601745-B2 | Heterocyclic NF-kB inhibitors | 4SC AG (DE) | 2009-10-13 | — | — | US | disclosed |
| US-20060247253-A1 | Novel heterocyclic NF-kB inhibitors | 4 SC AG (DE) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKB2, NFKBIA, NFRKB | EGLN1 2945/4885GRIN2D 2512/4885GRIN3B 1344/4885 |
| US-20140228378-A1 | N-(Benzimimdazol-2-yl)-Cyclopropane Carboxamides as Lysophosphatidic Acid Antagonists | LPAR5, LPAR2, LPAR1 | EGLN1 1145/4885GRIN2D 4355/4885GRIN3B 4774/4885 |
| US-20100048574-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | NFKBIA, IKBKB, NFKB2 | EGLN1 2162/4885GRIN2D 3926/4885GRIN3B 3111/4885 |
| US-20060247253-A1 | Novel heterocyclic NF-kB inhibitors | NFKBIA, NFRKB, NFKB2 | EGLN1 2847/4885GRIN2D 3223/4885GRIN3B 1033/4885 |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | EGLN1 1893/4885GRIN2D 1017/4885GRIN3B 438/4885 |
| US-20100004258-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKBIA, IKBKB, NFKB2 | EGLN1 2105/4885GRIN2D 4226/4885GRIN3B 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.